clinical trial · NCT06751121
Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori
Daewoong Pharmaceutical Co. LTD.·phase3·completed·n = 461
Helicobacter Pylori InfectionHelicobacter Pylori Infected PatientsHelicobacter Pylori Infected SubjectsDWP14012 40mgDWC202301 30mgAmoxicillin 1000mgClarithromycin 500mgDWC202301 30mg placeboDWP14012 40mg placebo
brief summary
This study is designed to demonstrate the non-inferiority and verify the safety of DWP14012-based triple therapy compared to DWC202301-based triple therapy as the first-line eradication therapy in patients who are positive for Helicobacter pylori
started
Feb 6, 2024
primary completion
Apr 24, 2025
completion
Apr 24, 2025
last updated
Dec 8, 2025
official title
A Multi-center, Randomized, Double-blind, Parallel-group, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol